CME Group

Christopher Bowen Managing Director and Chief Regulatory Counsel Legal Department

December 10, 2013

VIA E-MAIL

Ms. Melissa Jurgens Office of the Secretariat Commodity Futures Trading Commission Three Lafayette Centre 1155 21st Street, N.W. Washington, D.C. 20581

CONFIDENTIAL TREATMENT REQUESTED

RE: SUPPLEMENTAL SUBMISSION: NYMEX Submission No. 13-415S: Additional Supplemental Information Relating to the NYMEX Natural Gas and Power Incentive Program for Commercial Firms. Subject to a Freedom of Information Act Protection.

Dear Ms. Jurgens:

Previously, pursuant to Submission No. 13-415 dated December 10, 2013, the New York Mercantile Exchange, Inc. ("NYMEX" or "Exchange") notified the Commodity Futures Trading Commission ("CFTC" or "Commission") that it planned to modify its NYMEX Natural Gas and Power Incentive Program for Commercial Firms ("Program").

In this letter, the Exchange is providing the Commission with certain additional information related to the incentives under the Program. The additional supplemental information is provided in Appendix A, for which a request for confidential treatment is being simultaneously submitted to the Commission. A copy of that request for confidential treatment is included with this supplemental filing.

Modifications to the Program appear below, with additions underscored and deletions overstruck.

NYMEX certifies that the Program complies with the Commodity Exchange Act ("CEA") and the regulations thereunder. A concise explanation and analysis of the operation, purpose and effect of the Program was provided in Submission No. 13-415. There were no substantive opposing views to this Program.

The Exchange certifies that this submission has been concurrently posted on the Exchange's website at <u>http://www.cmegroup.com/market-regulation/rule-filings.html</u>.

If you require any additional information regarding this submission, please contact Tim Elliott at 312-466-7478 or via e-mail at <u>tim.elliott@cmegroup.com</u>, or contact me at 212-299-2200. Please reference our NYMEX Submission No. 13-415S in any related correspondence.

Sincerely,

/s/ Christopher Bowen Managing Director and Chief Regulatory Counsel

Attachment: Appendix A

1 North End Avenue New York, NY 10282 T 212 299 2200 F 212 299 2299 christopher.bowen@cmegroup.com cmegroup.com



Christopher Bowen Managing Director and Chief Regulatory Coursel Legal Department

December 10, 2013

VIA E-MAIL

Ms. Melissa Jurgens Office of the Secretariat Commodity Futures Trading Commission Three Lafayette Centre 1155 21st Street, N.W. Washington, D.C. 20581



Re: FOIA Confidential Treatment Request

Dear Ms. Jurgens:

By e-mail dated today, December 10, 2013, the New York Mercantile Exchange, Inc. ("NYMEX" or the "Exchange") submitted a supplemental rule certification filing (Submission No. 13-415S) to the Commodity Futures Trading Commission ("CFTC" or "Commission"). This supplemental filing includes an appendix ("Appendix A"), which is attached.

Pursuant to Sections 8 and 8(a) of the Commodity Exchange Act ("CEA"), as amended, and Commission Regulation 145.9(d), the Exchange requests confidential treatment of Appendix A on the grounds that Appendix A contains confidential commercial information of the submitters (the Exchange). A detailed written justification for this request is attached hereto as Exhibit 1. Pursuant to Commission Regulation 145.9(d)(5), NYMEX requests that confidential treatment be maintained for Appendix A <u>until further notice</u> from the Exchange. We also request that the Commission notify the undersigned immediately after receiving any FOIA request for said Appendix A or any other court order, subpoena or summons for same. Finally, we request that we be notified in the event the Commission intends to disclose such Appendix A to Congress or to any other governmental agency or unit pursuant to Section 8 of the CEA. The Exchange does not waive its notification rights under Section 8(f) of the CEA with respect to any subpoena or summons for such Appendix A.

Please contact the undersigned at (212) 299-2200 should you have any questions concerning this letter.

Sincerely,

/s/ Christopher Bowen Managing Director and Chief Regulatory Counsel

Enclosure: Exhibit 1